| 发明名称 | Formulation of human antibodies for treating TNF-α associated disorders | ||
| 摘要 | A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability. | ||
| 申请公布号 | US9302011(B2) | 申请公布日期 | 2016.04.05 |
| 申请号 | US201514884279 | 申请日期 | 2015.10.15 |
| 申请人 | ABBVIE BIOTECHNOLOGY LTD | 发明人 | Krause Hans-Juergen;Baust Lisa;Dickes Michael |
| 分类号 | A61K39/395;C07K16/00;C07K16/22;A61K47/26;A61K9/19;C07K16/24;A61K9/00;A61K47/10;A61K47/12;A61K47/22;A61K47/18;A61K47/02;C07K14/525;A61K39/00 | 主分类号 | A61K39/395 |
| 代理机构 | Ropes & Gray LLP | 代理人 | Ropes & Gray LLP ;Haley, Jr. James F.;Gummow Brian M. |
| 主权项 | 1. A stable liquid aqueous pharmaceutical formulation comprising (a) 50 mg/ml of a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody, wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:1 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 2; (b) a polyol; (c) a polysorbate; and (d) a buffer system comprising an organic acid; wherein the formulation has a pH of 4 to 8, and wherein the formulation is suitable for subcutaneous injection. | ||
| 地址 | Hamilton BM | ||